Dec 6, 2019 This Week in Cardiology Dec 6, 2019 This Week in Cardiology
Vernakalent, CV death in cancer patients, dapagliflozin, and sacubitril/valsartan are the topics Dr. John Mandrola discusses in this week ' s podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 6, 2019 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
Sun Pharma gets partial relief from US court in litigation involving three generic drugs
Drug major Sun Pharma is a defendant in a multi-district litigation brought by various classes of plaintiffs in the US District Court (District of Massachusetts), alleging a delay in the market entry for three generic drugs -- Valganciclovir, Valsartan and Esomeprazole. The company said it would continue to vigorously defend against all claims. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 1, 2019 Category: Pharmaceuticals Source Type: news
Making Room for New Drugs for Heart Failure Making Room for New Drugs for Heart Failure
Drs Ileana Pi ñ a and Mary Walsh discuss the latest HF updates from the American Heart Association Scientific Sessions and ask where dapagliflozin and sacubitril/valsartan will fit in the armamentarium.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 26, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Valsartan Recalls Took Toll on Patients' Health
WEDNESDAY, Nov. 20, 2019 -- Emergency room visits for high blood pressure surged following last year ' s recall of the popular heart drug valsartan, Canadian researchers report.
Within the first month of the recall, there was a 55% increase of people... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 20, 2019 Category: General Medicine Source Type: news
Recalls of Blood Pressure Med Took Toll on Patients' Health
WEDNESDAY, Nov. 20, 2019 -- Emergency room visits for high blood pressure surged following last year ' s recall of the popular heart drug valsartan, Canadian researchers report.
Within the first month of the recall, there was a 55% increase of people... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 20, 2019 Category: General Medicine Source Type: news
AHA: Impact of Valsartan Recall Examined for Ontario, Canada
MONDAY, Nov. 18, 2019 -- The generic valsartan recall has had population-level impacts on patients in Ontario, Canada, according to a research letter published online Nov. 11 in Circulation to coincide with the annual meeting of the American Heart... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 18, 2019 Category: Pharmaceuticals Source Type: news
Sacubitril/Valsartan Benefits Extend to HF With Mildly Reduced EF Sacubitril/Valsartan Benefits Extend to HF With Mildly Reduced EF
Further analysis of the PARAGON trial also suggest the benefit of the drug combination may reach higher ejection fractions in women.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 17, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Mylan hit with warning letter for valsartan manufacturing
The FDA sent a Mylan facility in India a warning letting for its manufacturing of APIs related to the widespread recall of blood pressure medications. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 13, 2019 Category: Pharmaceuticals Source Type: news
Generic Valsartan Abandoned After Recalls, ED Visits Rise Generic Valsartan Abandoned After Recalls, ED Visits Rise
Patients may have been willing to risk the short-term potential of uncontrolled hypertension to avoid ingesting a potential carcinogen in recalled generic valsartan medications, the authors say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 13, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
ER visits jumped after valsartan blood pressure medication recall, study says
After issuing a recall due to an impurity called NDMA, Health Canada urged patients not to stop taking their hypertension medications without consulting their health-care providers, but some may not have listened. (Source: CBC | Health)
Source: CBC | Health - November 12, 2019 Category: Consumer Health News Tags: News/Health Source Type: news
Aurobindo Pharma under USFDA scrutiny
Aurobindo has seen intense scrutiny on the manufacturer process of valsartan, an anti-hypertension drug, that was found to contain carcinogenic impurities. Apart from Aurobindo, those impurities were detected in several other batches manufactured by drug makers. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 4, 2019 Category: Pharmaceuticals Source Type: news
valsartan, Diovan
Title: valsartan, DiovanCategory: MedicationsCreated: 3/26/1998 12:00:00 AMLast Editorial Review: 10/17/2019 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - October 17, 2019 Category: Cardiology Source Type: news
Exercise essential for people diagnosed with cancer
Offer cancer patients tailored exercise prescription to protect their heart from damage, even before they start chemo Related items fromOnMedica Cancer patients using complementary meds die sooner Is crowdfunding for cancer patients paying for ‘quackery’? Exercise and psychological treatments cut cancer fatigue Withdrawn valsartan meds not linked to short-term cancer risk Cigars and pipes raise mortality risk independent of cigarettes (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 7, 2019 Category: UK Health Source Type: news
PROVE-HF Cracks the'Holy Grail' of Cardiac Remodeling in HFrEF PROVE-HF Cracks the'Holy Grail' of Cardiac Remodeling in HFrEF
Ileana Pi ñ a, MD speaks with lead author Jim Januzzi, MD, about the path to PROVE-HF and how sacubitril/valsartan benefits real-world patients with heart failure with reduced ejection fraction.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 7, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news
FDA Clears Sacubitril/Valsartan for Children With Heart Failure FDA Clears Sacubitril/Valsartan for Children With Heart Failure
Sacubitril/valsartan is approved to treat symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients 1 year and older.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 3, 2019 Category: Cardiology Tags: Cardiology News Alert Source Type: news
